CXCR4 Antagonist AMD3100 Protects Blood-Brain Barrier Integrity and Reduces Inflammatory Response After Focal Ischemia in Mice [Original Contributions]

Conclusions— CXCR4 antagonist AMD3100 significantly suppressed inflammatory response and reduced blood–brain barrier disruption after MCAO. AMD3100 attenuated ischemia-induced acute inflammation by suppressing leukocyte migration and infiltration, in addition to reducing proinflammatory cytokine expression in the ischemic region.

http://stroke.ahajournals.org/cgi/content/short/44/1/190?rss=1

Source: Stroke - December 24, 2012 Category: Neurology Authors: Huang, J., Li, Y., Tang, Y., Tang, G., Yang, G.-Y., Wang, Y. Tags: Animal models of human disease, Arterial thrombosis, Acute Cerebral Infarction, Behavioral Changes and Stroke, Brain Circulation and Metabolism, Other Stroke Treatment - Medical, Other Research Original Contributions Source Type: research